Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcNK-Sup003 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973Phase 1Recruiting
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Cell Therapies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AcNK-Sup003 in B-cell non-Hodgkin lymphoma. Primary endpoints: Dose-limiting toxicities at Day 28, Serious Adverse Events at 2 years and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
AcNK-Sup003
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06693973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693973.